Plain-English translation of NCT07489495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether — a targeted therapy already used for kidney cancer — works better when combined with another new targeted therapy called . Half of the participants will receive both medications together, and half will receive with a placebo (a pill with no active medication). The goal is to see if the combination helps people with advanced kidney cancer live longer and prevents the cancer from getting worse.
Some people with advanced kidney cancer have already tried other treatments (like immunotherapy or anti-angiogenic drugs) and the cancer has continued to grow. This trial is looking for a better treatment option for these patients by combining two targeted therapies that work in different ways.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take one pill by mouth once daily for about 24 months — either the new combination treatment or with a placebo. You will not know which group you are in. You will need to visit the research clinic regularly so doctors can check how you are responding to treatment, monitor you for side effects, and do blood tests and imaging scans to track your cancer.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States
Argentina